Treating prolactinomas with dopamine agonists: always worth the gamble?

Sean Noronha, Victoria Stokes, Niki Karavitaki, Ashley Grossman

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

Original languageEnglish
Early online date4 Sept 2015
Publication statusE-pub ahead of print - 4 Sept 2015


  • Bromocriptine
  • Cabergoline
  • Impulse control
  • Gambling
  • Hypersexuality


Dive into the research topics of 'Treating prolactinomas with dopamine agonists: always worth the gamble?'. Together they form a unique fingerprint.

Cite this